F|T: The FinTech Times – Boardroom skirmishes prevent Klarna’s IPO prep
Plus: FINTRAC “incident” shows cyberattacks are getting too easy.
Newsletters
Reflecting on inclusion in #CDNtech
Plus: The new venture studio backed by Shopify, Wealthsimple, Knix execs.
H|T: The Healthtech Times – Canadian pharmaceutical research spending dropped in 2022
Plus: Myanmar Molecular seeks Health Canada approval.
R|T: The Retail Times – Thrasio raised $3 billion. Now it’s filing for bankruptcy.
Plus: US resistance has Shein eyeing UK to IPO.
A|I: The AI Times – Cohere will cover its customers sued for copyright violations
Plus: Six months after launch, Toronto’s Ideogram secures $80 million.
S|W: The SaaS Weekly – Why is Marc Benioff buying up Hawaiian land?
Plus: Certn’s new president targets growth over acquisitions.
F|T: The FinTech Times – Stripe’s $65B valuation indicates an IPO isn’t anytime soon
Plus: How Flinks is building middleware for open banking.
Does corporate VC have an advantage in AI investments?
Plus: Omnirobotic reborn and Flinks moves in for the kill.
H|T: The Healthtech Times – Apple Vision Pro goes to the hospital
Plus: Abridge raises $150 million to increase the speed and accuracy of medical note-taking.
R|T: The Retail Times – Temu and Shein’s success = air freighters’ stress
Plus: Shopify’s green strategy gamble, DeliveryHero abandons Foodpanda sale talks.
A|I: The AI Times – Nvidia rides the AI wave to a $2-trillion valuation
Plus: Yoshua Bengio calls for deepfake regulations.
S|W: The SaaS Weekly – Reddit’s power users will get first dibs on its IPO
Plus: Golden Ventures talks success in closing fifth seed-stage VC fund.
F|T: The FinTech Times – BC court upholds ban on crypto mining, Sequoia backpedals Klarna ousting
Plus: Capital One’s blockbuster acquisition to protect itself from FinTech.
Is AI Canada’s productivity saviour?
Plus: Late-stage VC funding continues to drop, but seed-stage is Golden.
H|T: The Healthtech Times – Healwell CEO dishes on evolution from clinics to AI
Plus: Newfoundland wants to be a biotech hub.